

# 1 Individual Prediction of Psychotherapy Outcome in Posttraumatic Stress 2 Disorder using Neuroimaging Data

3 Paul Zhutovsky (MSc)<sup>1,2</sup>, Rajat M. Thomas (PhD)<sup>1,2</sup>, Miranda Olf (PhD)<sup>1,3</sup>, Sanne J.H. van Rooij (PhD)<sup>4</sup>,  
4 Mitzy Kennis (PhD)<sup>5</sup>, Guido A. van Wingen (PhD)<sup>1,2\*</sup>, Elbert Geuze (PhD)<sup>6,7\*</sup>

5 <sup>1</sup>Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience,  
6 Amsterdam, The Netherlands

7 <sup>2</sup>Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, The Netherlands

8 <sup>3</sup>Arq Psychotrauma Expert Group, Diemen, The Netherlands

9 <sup>4</sup>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta,  
10 GA, USA

11 <sup>5</sup>Clinical Psychology Department, Utrecht University, Utrecht, The Netherlands

12 <sup>6</sup>Utrecht University Medical Center, Rudolf Magnus Institute of Neuroscience, Utrecht, The  
13 Netherlands

14 <sup>7</sup>Brain Research and Innovation Center, Ministry of Defense, Utrecht, The Netherlands

15 \*Equally contributing authors

16

17 Contact information:

18 **Paul Zhutovsky**, paul.zhutovsky@gmail.com

19 Academic Medical Center, University of Amsterdam; Department of Psychiatry, Meibergdreef 5, PA3-  
20 118, 1105 AZ, Amsterdam, The Netherlands

## 21 Acknowledgments

22 This study was supported by the Dutch Ministry of Defense, the Netherlands Organization for Scientific  
23 Research (NWO/ZonMW Vidi 016.156.318) and the AMC Research Council (150622).

1 **Abstract**

2 **Objective:** Trauma-focused psychotherapy is the first-line treatment for posttraumatic stress disorder  
3 (PTSD) but 30-50% of patients do not benefit sufficiently. We investigated whether structural and  
4 resting-state functional magnetic resonance imaging (MRI/rs-fMRI) data could distinguish between  
5 treatment responders and non-responders on the group and individual level.

6 **Methods:** Forty-four male veterans with PTSD underwent baseline scanning followed by trauma-  
7 focused psychotherapy. Voxel-wise gray matter volumes were extracted from the structural MRI data  
8 and resting-state networks (RSNs) were calculated from rs-fMRI data using independent component  
9 analysis. Data were used to detect differences between responders and non-responders on the group  
10 level using permutation testing, and the single-subject level using Gaussian process classification with  
11 cross-validation.

12 **Results:** A RSN centered on the bilateral superior frontal gyrus differed between responders and non-  
13 responder groups ( $P_{FWE} < 0.05$ ) while a RSN centered on the pre-supplementary motor area  
14 distinguished between responders and non-responders on an individual-level with 81.4% accuracy ( $P$   
15  $< 0.001$ , 84.8% sensitivity, 78% specificity and AUC of 0.93). No significant single-subject classification  
16 or group differences were observed for gray matter volume.

17 **Conclusions:** This proof-of-concept study demonstrates the feasibility of using rs-fMRI to develop  
18 neuroimaging biomarkers for treatment response, which could enable personalized treatment of  
19 patients with PTSD.

## 1 Introduction

2 Posttraumatic stress disorder (PTSD) is a psychiatric disorder which can develop after experiencing a  
3 traumatic event. It is characterized by states of re-experiencing of the traumatic event, avoidance of  
4 trauma-reminders, emotional numbing, and hyperarousal (1). PTSD lifetime prevalence rates in the  
5 general population are estimated to be below 10% (varying between 1.3% to 8.8% depending on the  
6 country) (2) but can vary heavily in veterans (between 1.4% to 31%) (3, 4). Treatment of PTSD typically  
7 involves trauma-focused psychotherapy with or without the administration of medication such as  
8 selective serotonin reuptake inhibitors (SSRIs). Trauma-focused therapies such as trauma-focused  
9 cognitive behavior therapy (TF-CBT) or eye movement desensitization and reprocessing (EMDR) have  
10 been suggested as first-line treatments for treating PTSD (5). However, 30-50% of patients do not  
11 benefit sufficiently (6). To improve treatment response rates it is important to better understand  
12 differences between responders and non-responders, and identify reliable predictors for treatment  
13 outcome.

14 PTSD is characterized as a brain disorder showing differences in activity and connectivity of  
15 large-scale brain networks (7). The connectivity of these networks can be recorded using  
16 neuroimaging techniques such as resting-state functional magnetic resonance imaging (rs-fMRI).  
17 Therefore, it is important to investigate if those alterations in rs-fMRI connectivity could be used to  
18 predict treatment-outcome and reveal biomarkers to increase the treatment-response rate. Indeed,  
19 pre-treatment group differences in fMRI activity and connectivity were observed between responders  
20 and non-responders in PTSD in several studies (8-11). However, these group-level univariate analyses  
21 focus on average differences between responders and non-responders. This does not allow inference  
22 at the individual patient level, which can be achieved using multivariate supervised machine learning  
23 analyses (12). Most importantly, performance is evaluated on new data to estimate the  
24 generalizability of the trained models, and thereby enabling the prediction of treatment outcome for  
25 new patients. Machine learning analyses have been performed in the context of PTSD using different

1 modalities of MRI data to distinguish between patients and controls (13, 14). However, only two  
2 studies to date have used machine learning analyses to predict future outcome at an individual level.  
3 One study aimed to predict clinical status two years after treatment with 12 weeks of paroxetine in a  
4 sample of 20 civilian PTSD patients (15). This study used pre- and post-treatment rs-fMRI derived  
5 measures, amplitude of low frequency fluctuations and whole-brain degree centrality maps, and the  
6 results showed that pre- but not post-treatment measures were able to predict remission status after  
7 two years with an accuracy of 72.5%. But as all but one patient had been in remission shortly after  
8 treatment, these results reflect relapse rather than treatment outcome. In addition, one recent study  
9 used a combination of resting-state connectivity within the ventral attention network and delayed  
10 recall performance in a verbal memory task to predict the response to prolonged exposure therapy in  
11 ~19 civilian patients with PTSD (16). Although the proportion of treatment non-responders was low,  
12 the classifier still managed to distinguish the groups with  $\geq 80\%$  sensitivity and specificity.

13 To determine whether neuroimaging data could also predict treatment outcome in a larger  
14 sample of combat veterans with PTSD, we analyzed pre-treatment structural MRI and rs-fMRI data of  
15 44 patients who received treatment-as-usual. This consisted of trauma-focused psychotherapy such  
16 as TF-CBT and EMDR, and clinical outcome was determined 6-8 month following the baseline fMRI  
17 scan. We previously reported pre-treatment group differences in structural (17), white-matter (18)  
18 and task-based (f)MRI (8, 19) between responders and non-responders, as well as rs-fMRI differences  
19 between patients and controls (20) and post-treatment rs-fMRI differences between responders and  
20 non-responders (21). For the present study, we derived maps of regional gray matter volume using  
21 voxel-based morphometry (VBM). In addition, we extracted functional connectivity (FC) within  
22 resting-state networks (RSNs) using independent component analysis (ICA). To ensure independence  
23 between RSN identification and estimation of RSN expression for each individual patient, the ICA was  
24 performed on rs-fMRI data of sex and age matched combat controls (n=28). Subsequently, we  
25 performed univariate inference on the group level as well as multivariate prediction on the single-  
26 subject level using Gaussian process classification (GPC) with 10x10 cross-validation.

1

2

### 3 **Methods**

#### 4 **Participants**

5 In total 57 veterans with PTSD and 29 combat controls (CC) were included in the study. Patients were  
6 recruited from one of four outpatient clinics of the Military Mental Healthcare Organization in Utrecht,  
7 The Netherlands. PTSD diagnosis was established by a licensed psychologist or psychiatrist. The  
8 Clinician Administered PTSD scale (CAPS) (22) for DSM-IV (1) was administered by trained research  
9 staff to quantify the total symptom severity and had to be  $\geq 45$ . Combat controls had to have no current  
10 psychiatric disorders and a total CAPS score  $< 15$ . Further inclusion criteria for all subjects were  
11 deployment to a war zone and 18-60 years of age. Comorbid disorders were examined using the  
12 structured clinical interview for DSM-IV (SCID-I) (23). Subjects with a history of neurological disorders,  
13 current substance dependence and contraindications for MRI scanning were excluded. From the initial  
14 57 PTSD patients, seven were lost to follow-up, three were excluded based on excessive motion during  
15 scanning (see Supplemental Methods section), one due to an artifact in the MRI scan, and one due to  
16 refusal of scanning. One additional participant was excluded as she was the only female in the sample.  
17 This leads to the final sample of 44 PTSD patients. From the CCs only one subject had to be excluded  
18 based on excessive motion ( $n = 28$ ).

19 After a period of six to eight months in which patients underwent treatment-as-usual  
20 consisting of trauma-focused therapy (e.g. TF-CBT, EMDR) a second CAPS assessment was performed.  
21 Treatment response was defined as a  $\geq 30\%$  decrease of total CAPS score at follow-up with respect to  
22 the baseline assessment (24, 25). According to this criterion 24 PTSD veterans were defined as  
23 responder and 20 as non-responder. All participants gave written informed consent. The study was  
24 approved by the University Medical Center Utrecht ethics committee, in accordance with the  
25 declaration of Helsinki (26).

1

## 2 **Clinical Data Analysis**

3 To estimate whether the CCs, responders and non-responders differed across any demographic or  
4 clinical variables at baseline or follow-up ANOVA, Kruskal-Wallis,  $\chi^2$ , or t-tests were applied as  
5 appropriate. All tests were performed using the R software (version 3.5.1).

6

## 7 **Data Acquisition**

8 All scans were obtained on a 3T MRI scanner (Philips Medical System, Best, the Netherlands). The T1-  
9 weighted high resolution MRI scan was acquired before the rs-fMRI scan with the following  
10 parameters: repetition time (TR) = 10ms, echo time (TE) = 4.6ms, flip angle = 8°, 200 sagittal slices,  
11 field of view (FOV) = 240 x 240 x 160, matrix size = 304 x 299 and voxel size = 0.8 x 0.8 x 0.8mm. The  
12 rs-fMRI scan consisted of 320 T2\*-weighted echo planar interleaved slices with TR = 1600ms, TE =  
13 23ms, flip angle = 72.5°, FOV = 256 x 208 x 120, 30 transverse slices, matrix size = 64 x 51, total scan  
14 time 8 min and 44.8 s, 0.4 mm gap, acquired voxel size = 4 x 4 x 3.60mm). Participants were asked to  
15 focus on a fixation cross, while letting their mind wander and relax.

16

## 17 **MRI data preprocessing**

18 To estimate whether structural images carry information to distinguish between responders or non-  
19 responders a VBM analysis was performed. Gray matter (GM) voxel-wise volume maps were  
20 computed using the SPM12 toolbox (v7219, <https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>).

21 Resting-state fMRI images were preprocessed using the advanced normalization tools (ANTs, 2.1.0,  
22 <http://stnava.github.io/ANTs/>) and FMRIB Software Library (FSL, 5.0.10,  
23 <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/>). To control for the influence of motion on the rs-fMRI data ICA-  
24 AROMA was applied (27). Details on the preprocessing pipelines can be found in the Supplemental  
25 Methods section.

26

## 1 **Resting State Network Identification**

2 Preprocessed rs-fMRI data were analyzed to determine group-level resting-state networks (RSNs).  
3 Group components with a fixed number of 70 components were estimated using a meta-ICA approach  
4 utilizing FSL's MELODIC software (28) applied to the rs-fMRI data of the CCs. We chose to only use the  
5 CCs in this step to ensure that the definition of the RSNs and the machine learning analysis were  
6 independent from each other. The meta-ICA approach allows for the identification of reproducible  
7 and reliable group components (29). After meta-ICA, 48 RSN's were identified using a semi-automatic  
8 approach. Thereafter, FSL's dual regression approach was used to estimate single-subject spatial  
9 representations of the corresponding group networks for all patients. Details on the implementation  
10 and rationale of the procedure can be found in the Supplemental Methods section, and signal and  
11 noise components are illustrated in Supplemental Figure 1 and Supplemental Figure 2.

12

## 13 **Univariate Analysis**

14 The preprocessed GM volume maps from the VBM analysis and the identified RSNs were used to  
15 investigate group differences between responders and non-responders. Age and total intracranial  
16 volume were entered as covariates for the VBM data, while only age was used as covariate for the  
17 RSN data. The significance level was set to  $P < 0.05$  family-wise error (FWE) corrected and estimated  
18 using the threshold-free-cluster-enhancement statistic (TFCE) (30) with permutation testing (10000  
19 permutations) using the TFCE toolbox (r167, <http://dbm.neuro.uni-jena.de/tfce/>) for the VBM data.  
20 For the resting-state data, the PALM toolbox (a112, <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM>) was  
21 used, since it allowed for permutation-based FWE correction across the whole-brain and all 48 RSNs  
22 at the same time. Both analyses accounted for two-tailed tests.

23

## 24 **Multivariate Analysis**

25 For the multivariate single-subject classification of responders and non-responders, we used the GM  
26 volume-maps from the VBM analysis and each RSN separately. Classification was performed using a

1 Gaussian process classifier (GPC) (31). Briefly, GPCs are multivariate Bayesian classifiers which allow  
2 to obtain valid probabilistic predictions by estimating the posterior distribution, given a pre-defined  
3 prior distribution. Univariate feature selection was performed on the training set to reduce the initial  
4 data dimension using nested 5-fold cross-validation (see Supplemental Methods). Performance was  
5 estimated by calculating sensitivity, specificity, balanced accuracy, area under the receiver-operator  
6 curve (AUC) and positive/negative predictive value (PPV/NPV) using ten times repeated 10-fold cross-  
7 validation to avoid overfitting bias. To estimate whether our classifier performed better than chance,  
8 label permutation tests with 1000 iterations were performed. The final *P*-values were Bonferroni  
9 corrected for 49 tests.

10 We also investigated the performance of the GPC when an uncertainty option was allowed:  
11 utilizing the probabilistic output of the classifier, we established regions of uncertainty for which the  
12 classifier would not make a prediction. For example, with an uncertainty region of 10% any  
13 probabilistic GPC output for a new patient which lies between 45-55%, would not be assigned a  
14 classification label (because the classification into responders and non-responders would be  
15 uncertain). Only patients with a higher (or lower) probability would be assigned to a class and  
16 considered for calculation of balanced accuracy. This allowed us to investigate how well our GPC  
17 would perform if classification has only to be made if a specific level of certainty is reached and how  
18 many patients would need to be excluded to reach that level.

19

20

## 21 **Results**

### 22 **Clinical data**

23 Demographic information, clinical variables and outcomes of statistical tests can be found in Table 1.  
24 There was no difference in demographics between the CCs, responders or non-responders, nor any  
25 clinical difference between responders and non-responders at baseline. At follow-up non-responders



1 showed a higher total CAPS score ( $t(42) = 7.89, P < 0.001$ ) and higher use of serotonin reuptake  
2 inhibitors ( $\chi^2(1) = 5.77, P = 0.02$ ).

3

#### 4 **Univariate analysis**

5 After correction for multiple comparisons across all RSNs, the rs-fMRI analysis showed one network  
6 with significantly increased connectivity in non-responders as compared to responders (Figure 1). The  
7 network was centered on the bilateral lateral frontal polar area and the difference was observed in  
8 the right superior frontal gyrus ( $P_{FWE} = 0.04$ ). No significant group differences in GM were observed.

9

#### 10 **Multivariate analysis**

11 GPC's trained on a network centered around the pre-supplementary motor area (pre-SMA) could  
12 classify non-responders and responders with an average cross-validated balanced accuracy of 81.4%  
13 (SD: 17.2,  $P_{Bonferroni} < 0.05$ ) (Figure 2A). The network showed excellent AUC (0.929, SD: 0.149) with high  
14 sensitivity (84.8%, SD: 25.1), moderately high specificity (78% SD: 28.6), and high PPV/NPV  
15 (0.840/0.835, SD: 0.214/0.262). No other network showed significant classification performance after  
16 Bonferroni correction was applied, including the network that showed a significant difference on the  
17 group-level in the univariate analysis.

18 To investigate which regions of the pre-SMA network were most important for the  
19 classification process we examined consistently selected voxels during the feature selection process.  
20 We tracked the selection frequency of voxels across cross-validation runs, looking at voxels which  
21 were selected in >50% of the runs (Table 2 and Figure 3). Regions in both hemispheres located outside  
22 the group-network were contributing to the classification performance. The largest clusters were  
23 located in the left inferior temporal gyrus ( $n_{\text{voxel}} = 14$ ), left superior frontal gyrus ( $n_{\text{voxel}} = 10$ ), and right  
24 precentral gyrus ( $n_{\text{voxel}} = 9$ ).

25 Additionally, we provided a post-hoc evaluation of what would happen if prediction would  
26 only be made for patients for which a high degree of certainty of the classifier is established. As

1 illustrated in Figure 2B, this ability to ‘reject’ patients from the classification with increasing  
2 classification certainty leads to increasing accuracy while at the same time reducing the number of  
3 patients for which the GPC can make a classification. For example, once 12 patients (27%) with low  
4 prediction certainty of 0.41-0.59 – where 0.5 is equal probability of prediction – would be excluded,  
5 accuracy would increase to over 90%.

6

7

## 8 **Discussion**

9 The present study investigated the possibility of using pre-treatment structural MRI and rs-fMRI data  
10 to predict the response to trauma-focused psychotherapy in male combat veterans with PTSD. The  
11 results showed that rs-fMRI data successfully distinguished between responders and non-responders  
12 univariate and multivariate analyses. The univariate analysis detected group differences in a network  
13 centered on the frontal pole, and the multivariate analysis predicted treatment response on an  
14 individual level using pre-SMA connectivity with an accuracy of 81.4%. Whereas previous studies have  
15 focused on MRI-based treatment outcome predictors at the group level, our results suggest that  
16 single-subject prediction is also feasible. This result provides a proof-of-concept for the feasibility of  
17 developing predictive biomarkers, which could enable personalized treatment for patients with PTSD.

18 Our multivariate analysis revealed the predictive importance of the pre-SMA. This brain area  
19 is closely linked to the SMA and both areas are involved in motor execution and imagination. However,  
20 the pre-SMA can also be distinguished from the SMA, and is more involved in higher cognitive  
21 processes such as working memory, language and task switching (32, 33). Furthermore, the pre-SMA  
22 has been implicated to be involved in the process of response inhibition which has been previously  
23 related to PTSD development and treatment-response in PTSD (see (34) for a review). Therefore, the  
24 discovered network might relate to the level of cognitive control in these patients, however, future  
25 studies are needed to elucidate why individual differences within this network are important for PTSD  
26 trauma-focused therapy response. Intriguingly, resting-state connectivity within this network is also

1 predictive for the response to electroconvulsive therapy in depression (35). The main difference in  
2 results is that the network in the current study is more confined to the pre-SMA due to the use of ICA  
3 with 70 components instead of 32 components, which was associated with a larger network that  
4 consisted of a large part of the dorsomedial prefrontal cortex. Together, this suggests that pre-SMA  
5 connectivity may determine responsiveness to treatment, regardless of intervention and disorder.

6         The discovered network is different from the ventral attention network (VAN, consisting of  
7 the insula, dorsal anterior cingulate, anterior middle frontal gyrus, and supramarginal gyrus) that was  
8 recently reported. The VAN in combination with delayed recall performance in a verbal memory task  
9 could predict prolonged exposure therapy outcome in a sample of ~19 civilians with PTSD with  
10 sensitivity and specificity  $\geq 80\%$  (16). But even though both studies used rs-fMRI, the underlying  
11 biomarkers cannot readily be compared. First, the variables tested in (16) were discovered by  
12 performing comparisons between healthy controls and PTSD patients, whereas we discovered the pre-  
13 SMA network from comparisons between responders and non-responders directly. Second, the  
14 authors did not investigate any other networks beyond the VAN for treatment outcome prediction.  
15 And third, the brain regions that are part of the VAN were actually part of distinct RSNs in our ICA  
16 analysis, whereas the VAN was considered one network in the other study. Therefore, it remains to  
17 be tested whether VAN or pre-SMA connectivity is also predictive in other samples. Regardless, both  
18 studies demonstrate that rs-fMRI contains information that is informative for predicting  
19 psychotherapy outcome on an individual level.

20         The univariate group analysis showed increased connectivity in non-responders in the frontal  
21 pole. The frontal pole region (BA 10) has been implicated in a multitude of cognitive tasks, including  
22 attention, perception, language, and memory tasks (36, 37). Specifically, the lateral parts of the  
23 frontal pole are more associated with working memory and episodic memory retrieval while medial  
24 parts of the frontal pole were mostly involved in mentalizing, which is the reflection of your own  
25 emotions and mental states (36, 37). This division of the frontal pole was recently confirmed by a  
26 cytoarchitectonic parcellation indicating two distinct areas: a more lateral frontal pole area 1 (FP 1)

1 and a more medial frontal pole area 2 (FP 2). Our frontal polar network was mostly located in FP 1 and  
2 may therefore be associated with memory related processes. Interestingly, the frontal pole is  
3 particularly known for its role in metacognitive processes such as prospective memory, which refers  
4 to the ability to remember to perform an intended action in the future (38). Prospective memory  
5 allows maintaining and retrieving future goals and plans, which is expected to be relevant for the  
6 success of psychotherapy. Additionally, a proposed underlying mechanism of psychotherapy action is  
7 memory reconsolidation, which refers to the process of modifying maladapted memories (39). We  
8 therefore speculate that the observed difference in the FP 1 region might reflect one or both of these  
9 mechanisms.

10         The difference between the identified networks in the univariate and multivariate analyses  
11 might seem counterintuitive at first but can be explained by the differences in objective and  
12 methodology of both analyses. This discrepancy is in line with the observation that significant group-  
13 level differences do not necessarily translate to high classification accuracies because of strongly  
14 overlapping distributions and different goals of the analysis (12). A significant *P*-value in a group-level  
15 analysis does not have to correspond to the ability of distinguishing between individual patients  
16 because the statistically significant difference in average values might show low effect sizes. In these  
17 case classification performance will be low. In addition, the goal of statistical inference is the  
18 identification of localized differences between groups while the goal of classification is to find the best  
19 multivariate combination of data which would allow to generalize the effect to new subjects. These  
20 are two inherently different goals which therefore can lead to different outcomes.

21         In contrast to our results, previous studies that have used univariate analysis of structural MRI  
22 and task-based fMRI data have primarily pointed to pre-treatment differences in the anterior cingulate  
23 cortex, amygdala, hippocampus and insula (8-11). However, direct comparison with our study is  
24 difficult since these differences might be due to the use of task-based fMRI, usage of a predefined  
25 region of interest approach, different types of psychotherapy, different PTSD populations and  
26 different criteria for treatment response (40). This can be exemplified with the absence of results for

1 the structural MRI analysis which is in contrast to our previous finding of differences in hippocampal  
2 volume between patients with remitted vs. persistent PTSD (17). This difference could be due to the  
3 calculation of the volumes: in the present study, a VBM analysis was employed to provide a highly  
4 multivariate data set which could be optimally used during the classification procedure, whereas we  
5 previously estimated hippocampal volume using segmentation in Freesurfer. In addition, in this study  
6 we chose to focus on treatment response while previously we investigated the more stringent  
7 criterion of treatment remission to focus on PTSD persistence.

8         The current study has several limitations. Although the study is among the largest for  
9 treatment outcome prediction using neuroimaging in psychiatry, the sample size is small for machine  
10 learning analyses with many more features than subjects. This could result in high variance of the  
11 estimated accuracy and the results therefore require further validation in independent samples.  
12 Another limitation of this study is the use of an all-male veteran sample. This limits the generalization  
13 of the results to other patients with PTSD. Therefore, a replication of the proposed approach in a more  
14 diverse sample would be desirable. Finally, the treatments received by the patients represent a  
15 heterogeneous mix of different trauma-focused psychotherapies. While they are considered as first-  
16 line treatments and the fact that in realistic settings multiple treatments might be employed by  
17 psychiatrists, the results are not specific to one particular treatment. This can also be considered a  
18 strength, as the predictive power generalizes to different types of psychotherapy.

19         In conclusion, the current study shows that treatment response to trauma-focused  
20 psychotherapy can be predicted for individual patients with PTSD using machine learning analysis of  
21 rs-fMRI data. This proof-of-concept study demonstrates the feasibility to develop neuroimaging  
22 biomarkers for treatment response, which will enhance personalized treatment of patients with PTSD.

## 1 Tables and Figures

2 Table 1: Demographics and clinical data

	<b>Combat Controls (n = 28)</b>	<b>Responders (n = 24)</b>	<b>Non- Responders (n = 20)</b>	<b>Test-value(df), P-value</b>
Age (years)	37.00 (10.13)	33.25 (7.76)	38.65 (9.34)	$F(2, 69) = 2.057,$ $P = 0.136^a$
Gender (m/f)	28/0	24/0	20/0	
Handedness (left/ambidexter/right)	2/3/23	2/2/20	2/2/16	$\chi^2(4) = 0.207,$ $P = 0.995^b$
Education (ISCED)				
Own	6 [4.75, 7]	6 [5.75, 6]	5.5 [3, 6]	$\chi^2(2) = 4.005, P = 0.135^c$
Mother	3.5 [2, 6]	3 [2, 4]	3 [2, 6]	$\chi^2(2) = 1.325, P = 0.516^c$
Father	5 [2, 6.5]	3.5 [2.25, 7]	5 [2, 7]	$\chi^2(2) = 0.044, P = 0.978^c$
Time since last deployment (years)	5.89 (6.56)	6.71 (7.83)	8.05 (9.51)	$\chi^2(2) = 0.218, P = 0.897^c$
Number of times deployed (1/2/3/>3)	(10/8/4/6)	(9/5/3/7)	(8/3/6/2)	$\chi^2(2) = 0.416, P = 0.812$
FD	0.10 (0.04)	0.09 (0.05)	0.12 (0.07)	$\chi^2(2) = 3.278, P = 0.194^c$
TIV		1550.02 (121.15)	1528.06 (166.44)	$t(42) = -0.506, P = 0.616^d$

**Clinical scores at baseline**

CAPS	71.92 (15.06)	69.85 (11.45)	$t(42)=0.504, P = 0.617^d$
------	---------------	---------------	----------------------------

**Pre-treatment comorbid disorder baseline**

**(SCID)**

Mood disorder	13	10	$\chi^2(1) = 0.076, P = 0.783^b$
---------------	----	----	----------------------------------

Anxiety disorder	5	9	$\chi^2(1) = 2.937, P = 0.087^b$
------------------	---	---	----------------------------------

Somatoform disorder	1	1	$\chi^2(1) = 0.017, P = 0.895^b$
---------------------	---	---	----------------------------------

**Pre-treatment**

**Medication**

SRI	5	7	$\chi^2(1) = 1.104, P = 0.293^b$
-----	---	---	----------------------------------

Benzodiazepines	7	3	$\chi^2(1) = 1.247, P = 0.264^b$
-----------------	---	---	----------------------------------

Antipsychotics	2	0	$\chi^2(1) = 1.746, P = 0.186^b$
----------------	---	---	----------------------------------

Total number of treatment sessions	9.86 (6.29)	10.05 (4.22)	$t(38) = -0.114,$ $P = 0.910^d$
---------------------------------------	-------------	--------------	------------------------------------

**Clinical scores at post-treatment**

CAPS	29.75 (16.53)	68.55 (15.89)	$t(42) = 7.889,$ $P < 0.001^{d*}$
------	---------------	---------------	--------------------------------------

**Post-treatment comorbid disorder post-treatment (SCID)**

Mood disorder	3	3	$\chi^2(1) = 0.096, P = 0.757^b$
---------------	---	---	----------------------------------

Anxiety disorder	2	5	$\chi^2(1) = 2.516, P = 0.113^b$
------------------	---	---	----------------------------------

Somatoform disorder	0	1	$\chi^2(1) = 1.293, P = 0.256^b$
---------------------	---	---	----------------------------------

Alcohol dependency	0	2	$\chi^2(1) = 2.650, P = 0.104^b$
--------------------	---	---	----------------------------------

**Post-treatment**

**Medication**

SRI	5	11	$\chi^2(1) = 5.768,$ $P = 0.016^{b*}$
Benzodiazepines	5	1	$\chi^2(1) = 2.307, P = 0.129^b$
Antipsychotics	2	2	$\chi^2(1) = 0.040, P = 0.841^b$

- 
- 1 Abbreviations: ISCED: international scale for education; FD: framewise displacement; TIV: total
  - 2 intracranial volume; CAPS: clinician administered PTSD scale; SCID: structured clinical interview for
  - 3 DSM IV Axis II disorders; SRI: serotonin reuptake inhibitor
  - 4 <sup>a</sup> ANOVA
  - 5 <sup>b</sup>  $\chi^2$
  - 6 <sup>c</sup> Kruskal-Wallis
  - 7 <sup>d</sup> Two-sample t-test
  - 8 \*  $P < 0.05$




1 Table 2: Most frequently selected features during the nested-cross-validation procedure of the pre-  
 2 SMA network

Number of voxels	Max frequency within cluster (%)	MNI coordinates of max value (mm)	Region name
14	99	-52, 8, -34	Left inferior temporal gyrus
10	100	-24, 60, 22	Left superior frontal gyrus
9	100	64, 4, 14	Right precentral gyrus
7	100	-44, 8, -14	Left insula, left superior temporal pole
6	93	28, -80, 50	Right superior parietal lobule
6	100	0, -4, -2	Hypothalamus
4	98	0, 36, 58	Left medial frontal gyrus
4	89	32, 64, 6	Right middle frontal gyrus
4	96	48, -76, 18	Right middle occipital gyrus
2	92	0, -80, 46	Left precuneus
2	76	40, -84, 26	Right middle occipital gyrus
2	67	-44, 56, 2	Left middle frontal gyrus
2	75	48, 52, -6	Right middle orbitofrontal gyrus


2	63	36, 44, -18	Right inferior orbitofrontal gyrus
1	84	40, 56, -6	Right middle orbitofrontal gyrus
1	100	32, 64, 14	Right superior frontal gyrus
1	67	-4, 68, -10	Left medial orbitofrontal gyrus
1	57	4, -88, 34	Left cuneus
1	69	28, 8, 66	Right superior frontal gyrus

1



1

2 Figure 1. Results of the group-level univariate RSN analysis. Higher resting-state connectivity in non-  
3 responders than responders in the frontopolar network. Two-tailed  $P$ -value was corrected for whole-  
4 brain comparisons and 48 networks.



1

2 Figure 2. Results of the single-subject multivariate prediction analysis of treatment outcome. A)

3 Classification metrics of the pre-SMA network shown as box-and-whisker plots. Outliers plotted as

4 circles were determined as values which lay outside 1.5 times the interquartile range. Please note that


5 the box for the AUC metric collapsed because the first quartile and the median were the same value.

6 B) Post-hoc evaluation of accuracy of GPC classifier when a certain level of certainty has to be ensured

7 averaged across the ten repetitions of the 10-fold cross-validation with SD plotted as error bars. For

8 example, once 12 patients (27%) with low prediction certainty of 0.41-0.59 – where 0.5 is equal

9 probability of prediction – would be excluded, accuracy would increase to over 90%.



1

2 Figure 3. Best performing network in the multivariate classification (pre-SMA) in hot colors and the

3 most often selected voxels during the classification in cold colors.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23

## Supplementary Material

### Individual Prediction of Psychotherapy Outcome in Posttraumatic Stress Disorder using Neuroimaging Data

Paul Zhutovsky (MSc)<sup>1,2</sup>, Rajat M. Thomas (PhD)<sup>1,2</sup>, Miranda Olf (PhD)<sup>1,3</sup>, Sanne J.H. van Rooij (PhD)<sup>4</sup>,  
Mitzy Kennis (PhD)<sup>5</sup>, Guido A. van Wingen (PhD)<sup>1,2\*</sup>, Elbert Geuze (PhD)<sup>6,7\*</sup>

<sup>1</sup>Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, Amsterdam, The Netherlands

<sup>2</sup>Amsterdam Brain and Cognition, University of Amsterdam, Amsterdam, The Netherlands

<sup>3</sup>Arq Psychotrauma Expert Group, Diemen, The Netherlands

<sup>4</sup>Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA

<sup>5</sup>Clinical Psychology Department, Utrecht University, Utrecht, The Netherlands

<sup>6</sup>Utrecht University Medical Center, Rudolf Magnus Institute of Neuroscience, Utrecht, The Netherlands

<sup>7</sup>Brain Research and Innovation Center, Ministry of Defense, Utrecht, The Netherlands

\*Equally contributing authors

## 1 **Supplemental Methods**

### 2 **MRI processing**

3 The voxel-based morphometry (VBM) analysis was performed using the SPM12 toolbox. Briefly,  
4 we obtained gray matter (GM) segmentations applying the unified segmentation approach (41).  
5 The GM maps were then normalized to MNI space (1.5mm<sup>3</sup>) based on DARTEL registration (42)  
6 using a template derived from 555 healthy controls of the IXI-database ([http://www.brain-](http://www.brain-development.org)  
7 [development.org](http://www.brain-development.org)) in MNI space provided by the CAT12 toolbox ([http://www.neuro.uni-](http://www.neuro.uni-jena.de/cat/)  
8 [jena.de/cat/](http://www.neuro.uni-jena.de/cat/)). The normalized GM images were modulated by the Jacobian determinant to  
9 preserve local tissue volume and spatially smoothed with a kernel of 8mm at FWHM.

10

### 11 **fMRI processing**

12 Preprocessing of fMRI images was performed using the advanced normalization tools (ANTs,  
13 2.1.0, <http://stnava.github.io/ANTs/>) (43) and FMRIB Software Library (FSL, 5.0.10) (44). For  
14 the purpose of registration to MNI space and extraction of white matter (WM) and cerebral spinal  
15 fluid (CSF) signal from fMRI scans, T1 images were bias-field corrected using the N4 algorithm  
16 (45) and brain-extracted using scripts from the ANTs toolbox and the Oasis template  
17 (<https://www.oasis-brains.org/>). Images were then segmented into GM, WM and CSF partial  
18 volume estimates using FSL's FAST (46). The skull-stripped images were normalized to MNI  
19 space using the ANTs symmetric normalization procedure (43). One PTSD patient was excluded  
20 based of an artifact in his MRI scan.

21 fMRI image preprocessing consisted of realignment, co-registration to the T1 image using  
22 boundary-based registration (47) and spatial smoothing with a 8mm FWHM kernel. Motion has  
23 a strong effect on resting-state fMRI measures (48) and therefore has to be addressed further  
24 during the preprocessing of rs-fMRI data. Therefore, we calculated framewise displacement  
25 (FD) (49) of the raw data and excluded subjects based on the following criteria: (1) any  
26 rotation/translation parameter >4mm/°, (2) average FD > 0.45, (3) more than 150 volumes  
27 with an individual FD of 0.25, leading to less than 4min of motion free rs-fMRI data (50).

1 Applying these criteria led to the exclusion of three PTSD patients and one combat control. The  
2 remaining patients did not differ in their motion levels (see Table 1). Furthermore, motion was  
3 additionally addressed by applying ICA-AROMA (27) to automatically identify single-subject ICA  
4 components associated with motion. These components were then regressed out from the data.  
5 Further structured noise was removed by performing nuisance regression with average WM  
6 and CSF signals. For that the calculated WM/CSF segmentations of the T1 image were  
7 transformed to EPI space and thresholded conservatively at 0.95. The denoised fMRI images  
8 were transformed to MNI space at 4mm and high-pass filtered at 0.01Hz.

9

### 10 **Meta-ICA**

11 For the meta-ICA we repeatedly (25 times) extracted 20 participants out of the 28 combat  
12 controls at random and performed a temporally-concatenated group-ICA with the number of  
13 components fixed to 70. The obtained spatial maps ( $25 * 70 = 1750$ ) were merged and entered  
14 into an additional (meta-)ICA with 70 components. The number of components was determined  
15 because it was shown to provide good insight into clinical differences of patient groups (51).  
16 Following the meta-ICA, group spatial components were investigated visually and using an  
17 automatic approach verifying their reproducibility across individual ICA runs and the  
18 proportion of the components located in the gray matter (52). 48 components were identified  
19 as carrying non-noise related resting-state activity (Supplementary Figure 1 and Supplementary  
20 Figure 2). Following the identification of the components dual regression was performed to  
21 identify subject specific spatial maps corresponding to the group components (53). Dual  
22 regression was applied using the group maps computed through meta-ICA on the combat  
23 controls and the rs-fMRI data of the PTSD patients.

24


### 25 **Multivariate Analysis**

26 Classification was performed using a Gaussian process classifier (GPC). We chose a zero mean  
27 and a normalized linear kernel function for the prior distribution following recommendations in



1 the field (54). To infer the parameters of the posterior distribution we used a Probit likelihood  
2 function with the expectation maximization algorithm for inference (55). To reduce the initial  
3 dimensionality of the classification problem univariate feature selection was performed. For  
4 that we computed the average univariate difference between connectivity values in every voxel  
5 using only participants of the training set. The difference was then z-scaled and thresholded. To  
6 determine the optimal threshold we investigated z-values from 2.5 until 4.0 in steps of 0.1 using  
7 nested 5-fold cross-validation on the training set. The optimal value was chosen as the one  
8 which generated the highest average balanced accuracy (average between sensitivity and  
9 specificity) across the five folds. The GPC was implemented using the Python (version 2.7.15)  
10 interface of the Shogun machine learning toolbox (version 6.1.3, <http://shogun-toolbox.org/>).

11




1

2 *Supplementary Figure 1. 48 out of 70 networks calculated via a meta-ICA approach which were*

3 *identified as carrying signal-related information*

4



1

2 *Supplementary Figure 2. 22 out of 70 meta-ICA networks which were related to noise sources.*

3

4

5

6

7 **References**

- 1 1. American Psychiatric A: Diagnostic and statistical manual of mental disorders : DSM-IV. Washington, DC,  
2 American Psychiatric Association; 1994.
- 3 2. Atwoli L, Stein DJ, Koenen KC, McLaughlin KA. Epidemiology of posttraumatic stress disorder: prevalence,  
4 correlates and consequences. *Curr Opin Psychiatry*. 2015;28:307-311.
- 5 3. Richardson LK, Frueh BC, Acierno R. Prevalence estimates of combat-related post-traumatic stress disorder:  
6 critical review. *Aust N Z J Psychiatry*. 2010;44:4-19.
- 7 4. Sundin J, Fear NT, Iversen A, Rona RJ, Wessely S. PTSD after deployment to Iraq: conflicting rates,  
8 conflicting claims. *Psychol Med*. 2010;40:367-382.
- 9 5. Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC, Feltner C, Brownley KA, Olmsted KR,  
10 Greenblatt A, Weil A, Gaynes BN. Psychological treatments for adults with posttraumatic stress disorder: A  
11 systematic review and meta-analysis. *Clin Psychol Rev*. 2016;43:128-141.
- 12 6. Bradley R, Greene J, Russ E, Dutra L, Westen D. A multidimensional meta-analysis of psychotherapy for  
13 PTSD. *Am J Psychiatry*. 2005;162:214-227.
- 14 7. Fenster RJ, Lebois LAM, Ressler KJ, Suh J. Brain circuit dysfunction in post-traumatic stress disorder: from  
15 mouse to man. *Nat Rev Neurosci*. 2018;19:535-551.
- 16 8. van Rooij SJ, Geuze E, Kennis M, Rademaker AR, Vink M. Neural correlates of inhibition and contextual cue  
17 processing related to treatment response in PTSD. *Neuropsychopharmacology*. 2015;40:667-675.
- 18 9. Aupperle RL, Allard CB, Simmons AN, Flagan T, Thorp SR, Norman SB, Paulus MP, Stein MB. Neural  
19 responses during emotional processing before and after cognitive trauma therapy for battered women. *Psychiatry*  
20 *Res*. 2013;214:48-55.
- 21 10. Falconer E, Allen A, Felmingham KL, Williams LM, Bryant RA. Inhibitory neural activity predicts response to  
22 cognitive-behavioral therapy for posttraumatic stress disorder. *J Clin Psychiatry*. 2013;74:895-901.
- 23 11. Fonzo GA, Goodkind MS, Oathes DJ, Zaiko YV, Harvey M, Peng KK, Weiss ME, Thompson AL, Zack SE,  
24 Lindley SE, Arnow BA, Jo B, Gross JJ, Rothbaum BO, Etkin A. PTSD Psychotherapy Outcome Predicted by  
25 Brain Activation During Emotional Reactivity and Regulation. *Am J Psychiatry*. 2017;174:1163-1174.
- 26 12. Bzdok D, Ioannidis JPA. Exploration, Inference, and Prediction in Neuroscience and Biomedicine. *Trends*  
27 *Neurosci*. 2019.
- 28 13. Gong Q, Li L, Tognin S, Wu Q, Pettersson-Yeo W, Lui S, Huang X, Marquand AF, Mechelli A. Using  
29 structural neuroanatomy to identify trauma survivors with and without post-traumatic stress disorder at the  
30 individual level. *Psychol Med*. 2014;44:195-203.
- 31 14. Zhang Q, Wu Q, Zhu H, He L, Huang H, Zhang J, Zhang W. Multimodal MRI-Based Classification of Trauma  
32 Survivors with and without Post-Traumatic Stress Disorder. *Front Neurosci*. 2016;10:292.
- 33 15. Yuan M, Qiu C, Meng Y, Ren Z, Yuan C, Li Y, Gao M, Lui S, Zhu H, Gong Q, Zhang W. Pre-treatment  
34 Resting-State Functional MR Imaging Predicts the Long-Term Clinical Outcome After Short-Term Paroxetine  
35 Treatment in Post-traumatic Stress Disorder. *Front Psychiatry*. 2018;9:532.
- 36 16. Etkin A, Maron-Katz A, Wu W, Fonzo GA, Huemer J, Vértes PE, Patenaude B, Richiardi J, Goodkind MS,  
37 Keller CJ, Ramos-Cejudo J, Zaiko YV, Peng KK, Shpigel E, Longwell P, Toll RT, Thompson A, Zack S, Gonzalez  
38 B, Edelstein R, Chen J, Akingbade I, Weiss E, Hart R, Mann S, Durkin K, Baete SH, Boada FE, Genfi A, Autea J,  
39 Newman J, Oathes DJ, Lindley SE, Abu-Amara D, Arnow BA, Crossley N, Hallmayer J, Fossati S, Rothbaum BO,  
40 Marmar CR, Bullmore ET, O'Hara R. Using fMRI connectivity to define a treatment-resistant form of post-  
41 traumatic stress disorder. 2019;11:eaa13236.
- 42 17. van Rooij SJ, Kennis M, Sjouwerman R, van den Heuvel MP, Kahn RS, Geuze E. Smaller hippocampal  
43 volume as a vulnerability factor for the persistence of post-traumatic stress disorder. *Psychol Med*. 2015;45:2737-  
44 2746.
- 45 18. Kennis M, van Rooij SJ, Tromp do PM, Fox AS, Rademaker AR, Kahn RS, Kalin NH, Geuze E. Treatment  
46 Outcome-Related White Matter Differences in Veterans with Posttraumatic Stress Disorder.  
47 *Neuropsychopharmacology*. 2015;40:2434-2442.
- 48 19. van Rooij SJ, Kennis M, Vink M, Geuze E. Predicting Treatment Outcome in PTSD: A Longitudinal  
49 Functional MRI Study on Trauma-Unrelated Emotional Processing. *Neuropsychopharmacology*. 2016;41:1156-  
50 1165.
- 51 20. Kennis M, Rademaker AR, van Rooij SJ, Kahn RS, Geuze E. Resting state functional connectivity of the  
52 anterior cingulate cortex in veterans with and without post-traumatic stress disorder. *Hum Brain Mapp*.  
53 2015;36:99-109.
- 54 21. Kennis M, van Rooij SJ, van den Heuvel MP, Kahn RS, Geuze E. Functional network topology associated  
55 with posttraumatic stress disorder in veterans. *Neuroimage Clin*. 2016;10:302-309.
- 56 22. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development  
57 of a Clinician-Administered PTSD Scale. *J Trauma Stress*. 1995;8:75-90.
- 58 23. First MB, Spitzer RL, Gibbon M, Williams JB. Structured clinical interview for DSM-IV axis I disorders. New  
59 York: New York State Psychiatric Institute. 1995.
- 60 24. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM. Efficacy and safety of  
61 sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. *JAMA*. 2000;283:1837-1844.
- 62 25. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of  
63 sertraline and placebo in the treatment of posttraumatic stress disorder. *Arch Gen Psychiatry*. 2001;58:485-492.
- 64 26. World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research  
65 involving human subjects. *JAMA*. 2013;310:2191-2194.
- 66 27. Pruijm RHR, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust ICA-based  
67 strategy for removing motion artifacts from fMRI data. *Neuroimage*. 2015;112:267-277.

- 1 28. Beckmann CF, Smith SM. Probabilistic independent component analysis for functional magnetic resonance  
2 imaging. *IEEE Trans Med Imaging*. 2004;23:137-152.
- 3 29. Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, Beckmann CF, Adelstein JS, Buckner RL,  
4 Colcombe S, Dogonowski AM, Ernst M, Fair D, Hampson M, Hoptman MJ, Hyde JS, Kiviniemi VJ, Kotter R, Li  
5 SJ, Lin CP, Lowe MJ, Mackay C, Madden DJ, Madsen KH, Margulies DS, Mayberg HS, McMahon K, Monk CS,  
6 Mostofsky SH, Nagel BJ, Pekar JJ, Peltier SJ, Petersen SE, Riedl V, Rombouts SA, Rypma B, Schlaggar BL,  
7 Schmidt S, Seidler RD, Siegle GJ, Sorg C, Teng GJ, Veijola J, Villringer A, Walter M, Wang L, Weng XC,  
8 Whitfield-Gabrieli S, Williamson P, Windischberger C, Zang YF, Zhang HY, Castellanos FX, Milham MP. Toward  
9 discovery science of human brain function. *Proc Natl Acad Sci U S A*. 2010;107:4734-4739.
- 10 30. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold  
11 dependence and localisation in cluster inference. *Neuroimage*. 2009;44:83-98.
- 12 31. Rasmussen CE, Williams CKI: *Gaussian Processes for Machine Learning*. Cambridge, Massachusetts, The  
13 MIT Press; 2006.
- 14 32. Ruan J, Bludau S, Palomero-Gallagher N, Caspers S, Mohlberg H, Eickhoff SB, Seitz RJ, Amunts K.  
15 Cytoarchitecture, probability maps, and functions of the human supplementary and pre-supplementary motor  
16 areas. *Brain Struct Funct*. 2018;223:4169-4186.
- 17 33. Eickhoff SB, Bzdok D, Laird AR, Roski C, Caspers S, Zilles K, Fox PT. Co-activation patterns distinguish  
18 cortical modules, their connectivity and functional differentiation. *Neuroimage*. 2011;57:938-949.
- 19 34. van Rooij SJH, Jovanovic T. Impaired inhibition as an intermediate phenotype for PTSD risk and treatment  
20 response. *Prog Neuropsychopharmacol Biol Psychiatry*. 2019;89:435-445.
- 21 35. van Waarde JA, Scholte HS, van Oudheusden LJ, Verwey B, Denys D, van Wingen GA. A functional MRI  
22 marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression. *Mol*  
23 *Psychiatry*. 2015;20:609-614.
- 24 36. Bludau S, Eickhoff SB, Mohlberg H, Caspers S, Laird AR, Fox PT, Schleicher A, Zilles K, Amunts K.  
25 Cytoarchitecture, probability maps and functions of the human frontal pole. *Neuroimage*. 2014;93 Pt 2:260-275.
- 26 37. Gilbert SJ, Spengler S, Simons JS, Steele JD, Lawrie SM, Frith CD, Burgess PW. Functional specialization  
27 within rostral prefrontal cortex (area 10): a meta-analysis. *J Cogn Neurosci*. 2006;18:932-948.
- 28 38. Burgess PW, Wu H-C: Rostral Prefrontal Cortex (Brodmann Area 10). in *Principles of Frontal Lobe*  
29 *Function* 2013. pp. 524-544.
- 30 39. Lane RD, Ryan L, Nadel L, Greenberg L. Memory reconsolidation, emotional arousal, and the process of  
31 change in psychotherapy: New insights from brain science. *Behav Brain Sci*. 2015;38:e1.
- 32 40. Colvonen PJ, Glassman LH, Crocker LD, Buttner MM, Orff H, Schiehser DM, Norman SB, Afari N.  
33 Pretreatment biomarkers predicting PTSD psychotherapy outcomes: A systematic review. *Neurosci Biobehav*  
34 *Rev*. 2017;75:140-156.
- 35 41. Ashburner J, Friston KJ. Unified segmentation. *Neuroimage*. 2005;26:839-851.
- 36 42. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage*. 2007;38:95-113.
- 37 43. Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-  
38 correlation: evaluating automated labeling of elderly and neurodegenerative brain. *Med Image Anal*. 2008;12:26-  
39 44. Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. *Fsl*. *Neuroimage*. 2012;62:782-790.
- 40 45. Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, Gee JC. N4ITK: improved N3 bias  
41 correction. *IEEE Trans Med Imaging*. 2010;29:1310-1320.
- 42 46. Zhang Y, Brady M, Smith S. Segmentation of brain MR images through a hidden Markov random field model  
43 and the expectation-maximization algorithm. *IEEE Trans Med Imaging*. 2001;20:45-57.
- 44 47. Greve DN, Fischl B. Accurate and robust brain image alignment using boundary-based registration.  
45 *Neuroimage*. 2009;48:63-72.
- 46 48. Ciric R, Wolf DH, Power JD, Roalf DR, Baum GL, Ruparel K, Shinohara RT, Elliott MA, Eickhoff SB,  
47 Davatzikos C, Gur RC, Gur RE, Bassett DS, Satterthwaite TD. Benchmarking of participant-level confound  
48 regression strategies for the control of motion artifact in studies of functional connectivity. *Neuroimage*.  
49 2017;154:174-187.
- 50 49. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear  
51 registration and motion correction of brain images. *Neuroimage*. 2002;17:825-841.
- 52 50. Van Dijk KR, Hedden T, Venkataraman A, Evans KC, Lazar SW, Buckner RL. Intrinsic functional connectivity  
53 as a tool for human connectomics: theory, properties, and optimization. *J Neurophysiol*. 2010;103:297-321.
- 54 51. Abou Elseoud A, Littow H, Remes J, Starck T, Nikkinen J, Nissila J, Timonen M, Tervonen O, Kiviniemi V.  
55 Group-ICA Model Order Highlights Patterns of Functional Brain Connectivity. *Front Syst Neurosci*. 2011;5:37.
- 56 52. Cerliani L, Mennes M, Thomas RM, Di Martino A, Thoux M, Keyser C. Increased Functional Connectivity  
57 Between Subcortical and Cortical Resting-State Networks in Autism Spectrum Disorder. *JAMA Psychiatry*.  
58 2015;72:767-777.
- 59 53. Beckmann CF, Mackay CE, Filippini N, Smith SM. Group comparison of resting-state fMRI data using multi-  
60 subject ICA and dual regression. *Neuroimage*. 2009;47:S148.
- 61 54. Marquand A, Howard M, Brammer M, Chu C, Coen S, Mourao-Miranda J. Quantitative prediction of  
62 subjective pain intensity from whole-brain fMRI data using Gaussian processes. *Neuroimage*. 2010;49:2178-  
63 2189.
- 64 55. Minka TP: A family of algorithms for approximate Bayesian inference. Massachusetts Institute of Technology;  
65 2001.
- 66